FLXN insider filings
Flexion Therapeutics Inc — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2021-11-23. Screen FLXN transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for FLXN between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Flexion Therapeutics Inc
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2021-11-23 | 4 | Newtyn Management, LLC — 10% owner | Code (U): 5,900,000 | EDGAR |
| 2021-11-19 | 4 | Stejbach Mark — Director | Disposition to issuer (D): 12,631 @ $8.50 · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 7,000 (derivative) · +1 more | EDGAR |
| 2021-11-19 | 4 | Lukatch Heath — Director | Disposition to issuer (D): 9,000 @ $8.50 · Disposition to issuer (D): 9,000 (derivative) · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 7,000 (derivative) · Disposition to issuer (D): 7,000 (derivative) | EDGAR |
| 2021-11-19 | 4 | Kwo Elizabeth — Director | Disposition to issuer (D): 4,500 @ $8.50 · Disposition to issuer (D): 32,000 (derivative) · Disposition to issuer (D): 7,000 (derivative) | EDGAR |
| 2021-11-19 | 4 | Koppikar Utpal — Director | Disposition to issuer (D): 32,000 (derivative) | EDGAR |
| 2021-11-19 | 4 | Levine Mark S. — General Counsel | Disposition to issuer (D): 133,486 @ $8.50 · Disposition to issuer (D): 125,000 (derivative) · Disposition to issuer (D): 33,333 (derivative) · Disposition to issuer (D): 18,000 (derivative) · Disposition to issuer (D): 15,500 (derivative) · Disposition to issuer (D): 20,000 (derivative) | EDGAR |
| 2021-11-19 | 4 | Muzikant Adam — Chief Business Officer | Disposition to issuer (D): 103,666 @ $8.50 · Disposition to issuer (D): 40,000 (derivative) · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 16,667 (derivative) · Disposition to issuer (D): 11,000 (derivative) · Disposition to issuer (D): 20,000 (derivative) | EDGAR |
| 2021-11-19 | 4 | Layman Melissa — Chief Commercial Officer | Disposition to issuer (D): 103,956 @ $8.50 · Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 20,100 (derivative) | EDGAR |
| 2021-11-19 | 4 | Willwerth Christina — Chief Strategy Officer | Disposition to issuer (D): 141,241 @ $8.50 · Disposition to issuer (D): 25,830 (derivative) · Disposition to issuer (D): 32,000 (derivative) · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 5,000 (derivative) · Disposition to issuer (D): 20,000 (derivative) · +5 more | EDGAR |
| 2021-11-19 | 4 | Andrews William T. — Chief Medical Officer | Disposition to issuer (D): 34,250 @ $8.50 · Disposition to issuer (D): 205,500 (derivative) | EDGAR |
| 2021-11-19 | 4 | Clayman Michael D. — President and CEO, Director | Disposition to issuer (D): 335,498 @ $8.50 · Disposition to issuer (D): 373,769 @ $8.50 · Disposition to issuer (D): 24,600 @ $8.50 · Disposition to issuer (D): 388,683 @ $8.50 · Disposition to issuer (D): 136,530 (derivative) · Disposition to issuer (D): 200,000 (derivative) · +7 more | EDGAR |
| 2021-11-19 | 4 | Wentworth Kerry — Chief Regulatory Officer | Disposition to issuer (D): 140,843 @ $8.50 · Disposition to issuer (D): 6,000 @ $8.50 · Disposition to issuer (D): 24,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 20,000 (derivative) · +5 more | EDGAR |
| 2021-11-19 | 4 | Canute Scott A — Director | Disposition to issuer (D): 9,000 @ $8.50 · Disposition to issuer (D): 18,000 (derivative) · Disposition to issuer (D): 9,000 (derivative) · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 12,500 (derivative) · +3 more | EDGAR |
| 2021-11-19 | 4 | MAHAFFY PATRICK J — Director | Disposition to issuer (D): 39,824 @ $8.50 · Disposition to issuer (D): 18,000 (derivative) · Disposition to issuer (D): 18,000 (derivative) · Disposition to issuer (D): 18,000 (derivative) · Disposition to issuer (D): 18,000 (derivative) · Disposition to issuer (D): 18,000 (derivative) · +3 more | EDGAR |
| 2021-11-19 | 4 | MERRIFIELD C ANN — Director | Disposition to issuer (D): 19,000 @ $8.50 · Disposition to issuer (D): 18,000 (derivative) · Disposition to issuer (D): 9,000 (derivative) · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 12,500 (derivative) · +3 more | EDGAR |
| 2021-11-19 | 4 | MILINAZZO ALAN — Director | Disposition to issuer (D): 27,450 @ $8.50 · Disposition to issuer (D): 9,000 (derivative) · Disposition to issuer (D): 9,000 (derivative) · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 12,500 (derivative) · +3 more | EDGAR |
| 2021-11-19 | 4 | COLELLA SAMUEL D — Director | Disposition to issuer (D): 9,000 @ $8.50 · Disposition to issuer (D): 1,000 @ $8.50 · Disposition to issuer (D): 72,035 @ $8.50 · Disposition to issuer (D): 5,000 @ $8.50 · Disposition to issuer (D): 994,129 @ $8.50 · Disposition to issuer (D): 5,871 @ $8.50 · +12 more | EDGAR |
| 2021-11-19 | 4 | DRISCOLL FREDERICK W — Chief Financial Officer | Disposition to issuer (D): 30,680 @ $8.50 · Disposition to issuer (D): 168,000 (derivative) | EDGAR |
| 2021-08-04 | 4 | Andrews William T. — Chief Medical Officer | Grant/award (A): 34,250 @ $0 · Grant/award (A): 205,500 (derivative) @ $0 | EDGAR |
| 2021-07-20 | 4 | Willwerth Christina — Chief Strategy Officer | Sale (S): 3,945 @ $6.45 | EDGAR |
| 2021-07-20 | 4 | Muzikant Adam — Chief Business Officer | Sale (S): 1,870 @ $6.45 | EDGAR |
| 2021-07-20 | 4 | Levine Mark S. — General Counsel | Sale (S): 3,945 @ $6.45 | EDGAR |
| 2021-07-20 | 4 | Clayman Michael D. — President and CEO, Director | Tax withholding (F): 13,859 | EDGAR |
| 2021-07-20 | 4 | Wentworth Kerry — Chief Regulatory Officer | Sale (S): 3,944 @ $6.45 | EDGAR |
| 2021-07-12 | 4 | Koppikar Utpal — Director | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2021-06-28 | 4 | Kwo Elizabeth — Director | Grant/award (A): 4,500 @ $0 · Grant/award (A): 7,000 (derivative) @ $0 | EDGAR |
| 2021-06-28 | 4 | Stejbach Mark — Director | Grant/award (A): 4,500 @ $0 · Grant/award (A): 7,000 (derivative) @ $0 | EDGAR |
| 2021-06-28 | 4 | Lukatch Heath — Director | Grant/award (A): 4,500 @ $0 · Grant/award (A): 7,000 (derivative) @ $0 | EDGAR |
| 2021-06-28 | 4 | Muzikant Adam — Chief Business Officer | Grant/award (A): 2,081 @ $7.78 | EDGAR |
| 2021-06-28 | 4 | Clayman Michael D. — President and CEO, Director | Grant/award (A): 1,700 @ $7.78 | EDGAR |
| 2021-06-28 | 4 | Wentworth Kerry — Chief Regulatory Officer | Grant/award (A): 539 @ $7.78 | EDGAR |
| 2021-06-28 | 4 | Canute Scott A — Director | Grant/award (A): 4,500 @ $0 · Grant/award (A): 7,000 (derivative) @ $0 | EDGAR |
| 2021-06-28 | 4 | MAHAFFY PATRICK J — Director | Grant/award (A): 4,500 @ $0 · Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2021-06-28 | 4 | MERRIFIELD C ANN — Director | Grant/award (A): 4,500 @ $0 · Grant/award (A): 7,000 (derivative) @ $0 | EDGAR |
| 2021-06-28 | 4 | MILINAZZO ALAN — Director | Grant/award (A): 4,500 @ $0 · Grant/award (A): 7,000 (derivative) @ $0 | EDGAR |
| 2021-06-28 | 4 | COLELLA SAMUEL D — Director | Grant/award (A): 4,500 @ $0 · Grant/award (A): 7,000 (derivative) @ $0 | EDGAR |
| 2021-06-03 | 4 | DRISCOLL FREDERICK W — Chief Financial Officer | Grant/award (A): 28,000 @ $0 · Grant/award (A): 168,000 (derivative) @ $0 | EDGAR |
| 2021-05-12 | 4 | Arkowitz David — Chief Financial Officer | Sale (S): 2,229 @ $7.23 | EDGAR |
| 2021-03-23 | 4 | Clayman Michael D. — President and CEO, Director | Gift (G): 4,762 @ $0 · Gift (G): 21,099 @ $0 | EDGAR |
| 2021-03-16 | 4 | Layman Melissa — Chief Commercial Officer | Sale (S): 4,520 @ $11.80 | EDGAR |
| 2021-03-12 | 4/A | COLELLA SAMUEL D — Director | Other (J): 2,198 @ $0 | EDGAR |
| 2021-03-03 | 4 | Muzikant Adam — Chief Business Officer | Grant/award (A): 30,000 @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-03-03 | 4 | Willwerth Christina — Chief Strategy Officer | Grant/award (A): 30,000 @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-03-03 | 4 | Levine Mark S. — General Counsel | Grant/award (A): 30,000 @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-03-03 | 4 | Layman Melissa — Chief Commercial Officer | Grant/award (A): 20,100 @ $0 · Grant/award (A): 30,150 (derivative) @ $0 | EDGAR |
| 2021-03-03 | 4 | Clayman Michael D. — President and CEO, Director | Grant/award (A): 106,100 @ $0 · Grant/award (A): 159,150 (derivative) @ $0 | EDGAR |
| 2021-03-03 | 4 | Wentworth Kerry — Chief Regulatory Officer | Grant/award (A): 30,000 @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-03-03 | 4 | Arkowitz David — Chief Financial Officer | Grant/award (A): 30,000 @ $0 · Grant/award (A): 41,900 @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-03-03 | 4 | KELLEY SCOTT — Chief Medical Officer | Grant/award (A): 30,000 @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-01-29 | 4 | Clayman Michael D. — President and CEO, Director | Grant/award (A): 119,500 @ $0 · Tax withholding (F): 8,776 @ $12.37 | EDGAR |
Recent 8-K events — Flexion Therapeutics Inc
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2021-11-19 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 2.04 — Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-10-12 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-08-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-07-12 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2021-06-25 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2021-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-05-11 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-04-13 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-04-05 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2021-03-10 | 8-K | 2.02 — Results of Operations and Financial Condition 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=FLXN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs